Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05053659 · ClinicalTrials.gov registry record · Phase 1

Loncastuximab Tesirine and Venetoclax for Relapsed/ Refractory Non-Hodgkin Lymphoma

A Phase 1 study of Refractory Non-Hodgkin Lymphoma and Relapsed Non-Hodgkin Lymphoma, sponsored by Paolo Caimi, MD.

Active
Registry status
Phase 1
Development phase
23
Enrollment target
1
Study location

NCT05053659 is a Phase 1 study of Refractory Non-Hodgkin Lymphoma and Relapsed Non-Hodgkin Lymphoma that is active but no longer recruiting, run by Paolo Caimi, MD. The registered enrollment target is 23 participants, below the 95-participant average among 17 other Refractory Non-Hodgkin Lymphoma trials with a reported enrollment target (76% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05053659, a Phase 1 study of Refractory Non-Hodgkin Lymphoma and Relapsed Non-Hodgkin Lymphoma, is active but no longer recruiting, sponsored by Paolo Caimi, MD.

ACTIVE NOT RECRUITING
Registry status
Phase 1
Development phase
23 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to determine the correct dose and safety of combining two new cancer drugs, loncastuximab tesirine and venetoclax, as a treatment for relapsed or refractory B cell lymphoma.These drugs are used to treat some lymphomas, but have not yet been tested in combination for the treatment of lymphoma. The main goal of this study is to determine the safety of the combination.

Conditions Studied

Refractory Non-Hodgkin Lymphoma Relapsed Non-Hodgkin Lymphoma

Interventions

  • DRUG Venetoclax
  • DRUG Loncastuximab tesirine

Study Locations (1)

Ohio

  • Cleveland Clinic Taussig Cancer Center, Case Comprehensive Cancer Center - Cleveland

Trial Details

FieldValue
Enrollment Target 23 participants
Start Date 2022-06-20
Est. Completion 2026-06
Phase Phase 1

Sponsor

Paolo Caimi, MD

5 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05053659

The ClinicalTrials.gov registry entry for NCT05053659 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 23 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 95-participant average among 17 other Refractory Non-Hodgkin Lymphoma trials with a reported enrollment target (76% lower). The listed sponsor is Paolo Caimi, MD, which has 5 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Refractory Non-Hodgkin Lymphoma appearing as the primary indexed condition, and to 2 interventions - of which Venetoclax is the first listed.

NCT05053659 reports 1 study location spanning 1 distinct geographic area - top geographies include Ohio.

Frequently Asked Questions

What is clinical trial NCT05053659 about?

NCT05053659 is a clinical study titled "Loncastuximab Tesirine and Venetoclax for Relapsed/ Refractory Non-Hodgkin Lymphoma". The purpose of this study is to determine the correct dose and safety of combining two new cancer drugs, loncastuximab tesirine and venetoclax, as a treatment for relapsed or refractory B cell lymphoma.These drugs are used to treat some lymphomas, but have not yet been tested in combination for the ...

What is the current status of trial NCT05053659?

This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 23 participants. The study started on 2022-06-20. Estimated completion is 2026-06.

What conditions does trial NCT05053659 study?

This clinical trial studies the following conditions: Refractory Non-Hodgkin Lymphoma, Relapsed Non-Hodgkin Lymphoma.

What interventions are being tested in trial NCT05053659?

The interventions under investigation include: Venetoclax (DRUG), Loncastuximab tesirine (DRUG).

Who is sponsoring clinical trial NCT05053659?

This trial is sponsored by Paolo Caimi, MD, which has 5 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05053659 being conducted?

This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Refractory Non-Hodgkin Lymphoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Refractory Non-Hodgkin Lymphoma

All registered trials for this condition

Relapsed Non-Hodgkin Lymphoma

All registered trials for this condition

Ohio

All trials with a study site in Ohio

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.